NLG-0301: An open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC).
Ramaswamy Govindan
No relevant relationships to disclose
John Charles Morris
No relevant relationships to disclose
Gabriela R. Rossi
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics